THE US Food and Drug Administration (FDA) is actively looking into the potential misuse and abuse of gabapentinoids, a class of drugs that includes Pfizer's Neurontin (gabapentin) and Lyrica (pregabalin), which have been approved to treat a number of conditions such as postherpetic neuralgia, fibromyalgia and neuropathic pain.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 21 Feb 18
To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Feb 18
